Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03215927 · ClinicalTrials.gov registry record · Phase 2
Abatacept for the Treatment of Myositis-associated Interstitial Lung Disease
A Phase 2 study, sponsored by Rohit Aggarwal, MD.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT03215927: Completed Phase 2 study, sponsored by Rohit Aggarwal, MD.
NCT03215927 is a Phase 2 study that has completed, run by Rohit Aggarwal, MD. The registered enrollment target is 20 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (85% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03215927, a Phase 2 study, has completed, sponsored by Rohit Aggarwal, MD.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
A randomized, controlled pilot trial to evaluate the efficacy and safety of subcutaneous Abatacept in treating interstitial lung disease associated with the anti-synthetase syndrome.
Primary Outcome
The primary outcome criteria for efficacy will be the absolute change of % predicted FVC from the baseline visit to week 24 between the 2 treatment arms (SOC/placebo vs. SOC/Abatacept).
Interventions
- OTHER Placebo
- DRUG Abatacept
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2018-01-01 |
| Est. Completion | 2023-07-30 |
| Phase | Phase 2 |
What the finished NCT03215927 record still lists
NCT03215927 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (85% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03215927 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03215927 about?
NCT03215927 is a clinical study titled "Abatacept for the Treatment of Myositis-associated Interstitial Lung Disease". A randomized, controlled pilot trial to evaluate the efficacy and safety of subcutaneous Abatacept in treating interstitial lung disease associated with the anti-synthetase syndrome.
What is the current status of trial NCT03215927?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2018-01-01. Estimated completion is 2023-07-30.
What interventions are being tested in trial NCT03215927?
The interventions under investigation include: Placebo (OTHER), Abatacept (DRUG).
Who is sponsoring clinical trial NCT03215927?
This trial is sponsored by Rohit Aggarwal, MD, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03215927's enrollment target sits among peer trials
20 1805th of 2000 higher than 107 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI